首页
关于我们
关于开博锐
核心团队
成功案例
全球驻地
我们的服务
收并购
产权交易
融资
战略咨询
最新发布
联系我们
中文
English
中文
首页
关于我们
关于开博锐
核心团队
成功案例
全球驻地
我们的服务
收并购
产权交易
融资
战略咨询
最新发布
联系我们
中文
English
中文
KYBORA and ACA Pharma Partner to Accelerate Access to China’s Life Sciences Market
8 10 月, 2025
News
Strategic collaboration combin…
READ MORE
Key Biopharma Deals of 2024
16 1 月, 2025
News
Trends, Insights, an…
READ MORE
KYBORA Welcomes Stefan Bluemmers as Managing Director
13 1 月, 2025
News
Princeton, NJ – Janu…
READ MORE
Accelerated Approval (AA) and PRV Grant: Implications of the FDA’s Updated Guidance
9 1 月, 2025
News
Executive Summary&nb…
READ MORE
Empowering Dreams through Foundation Rwanda’s KYBORA Program
7 1 月, 2025
News
Ange’s Entrepreneuri…
READ MORE
Navigating the Complexities of Priority Review Vouchers in the Context of Accelerated Approval Withdrawals
19 12 月, 2024
News
Executive Summary&nb…
READ MORE
Recent Facts & Figures related to Priority Review Vouchers Value – 2020 to 2024
18 12 月, 2024
News
Executive Summary&nb…
READ MORE
European Pharma Group Proposes TEE Voucher System to Revitalize Antibiotics R&D
10 12 月, 2024
News
Executive Summary – …
READ MORE
KYBORA Advises Xbrane on Global Licensing Agreement with Intas
5 12 月, 2024
News
KYBORA, a leading gl…
READ MORE
Navigating Priority Review Voucher Eligibility: Beyond Rare Pediatric Disease Designation
4 12 月, 2024
News
Executive Summary&nb…
READ MORE
Understanding the Role of the Not Same Active Moiety Principle in RPDD and PRV Evaluations
2 12 月, 2024
News
Executive Summary&nb…
READ MORE
The Latest Trends on Biotech Companies with Negative Enterprise Values: Insights and Implications
13 8 月, 2024
News
In the post Covid er…
READ MORE
KYBORA Advises Lupin on the Divestiture of U.S. Commercial Women’s Health Specialty Business to Evofem
1 8 月, 2024
News
Global pharma major …
READ MORE
«
‹
2
3
4
5
6
›
»
TYPE & ENTER:
Close
